China's cardiovascular interventional device market reached ¥50.06 billion in 2023, growing at 12.87% CAGR. All cardiovascular implantable devices are Class III — NMPA's highest tier — requiring rigorous safety and efficacy evidence. By end-2024, domestic and imported registrations stood nearly equal at 186 vs 194, reflecting rapid domestic innovation. Overseas clinical data is accepted for registration when scientifically sound and applicable to the Chinese patient population.
Cardiovascular implantable and interventional devices occupy a unique position in China's medical device market: they represent the highest engineering complexity, the most stringent regulatory requirements, and one of the fastest-growing segments by value. With 330 million cardiovascular patients in China and 4.58 million annual deaths from cardiovascular disease, the clinical need is vast — and the commercial opportunity correspondingly significant.
This article provides a structured overview of the Chinese cardiovascular implant market, the regulatory framework governing these devices, the classification of key product categories, and the registration process that companies must navigate to achieve NMPA approval.
1. Market Overview: Scale and Structure
China's cardiovascular interventional device market reached ¥50.06 billion in 2023 — representing a 2017–2023 compound annual growth rate of approximately 12.87%. This rate significantly exceeds the growth of China's overall healthcare sector, driven by a combination of rising cardiovascular disease prevalence, aging demographics, expanding hospital procedure volumes, and technology-driven indication expansion.
By end-2024, the NMPA classification 13-07 (Cardiovascular Implants) contained 380 products with valid registration certificates: 194 imported and 186 domestic. The near-parity between domestic and imported registrations represents a remarkable shift from five years ago, when imported devices dominated the category. Domestic approvals in high-value subcategories — including transcatheter aortic valves, coronary stents, and cardiac occluders — have increased every year since 2020.
Key Product Categories
The cardiovascular implantable device landscape in China encompasses:
- Vascular stents — coronary drug-eluting stents (DES), peripheral vascular stents, carotid stents, aortic stents
- Heart valves and repair devices — surgical bioprosthetic and mechanical valves, transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral valve repair (e.g. edge-to-edge repair devices), chordae tendineae repair, annuloplasty rings
- Vascular grafts — synthetic vascular prostheses for aortic, coronary, and peripheral bypass procedures
- Cardiac occluders — atrial septal defect (ASD) occluders, ventricular septal defect (VSD) occluders, patent ductus arteriosus (PDA) occluders, patent foramen ovale (PFO) occluders
- Cardiac rhythm devices — implantable pacemakers, implantable cardioverter-defibrillators (ICD), cardiac resynchronisation therapy devices (CRT)
Technology Trends
Several technology trajectories are reshaping the cardiovascular implant category:
- Transcatheter approaches replacing open surgery — TAVR, transcatheter mitral repair, and transcatheter tricuspid valve interventions are converting procedures previously requiring high-risk open surgery to catheter-based techniques, dramatically expanding the eligible patient population
- Biodegradable scaffolds — bioresorbable coronary scaffolds that provide temporary structural support and then fully absorb, eliminating permanent metallic implant risks
- Intelligent monitoring integration — implantable devices with embedded sensors for remote haemodynamic monitoring, enabling proactive heart failure management
- Domestic material innovation — Chinese manufacturers developing proprietary alloys, polymers, and biological tissue processing methods to reduce dependence on imported components
2. Regulatory Classification: All Cardiovascular Implants Are Class III
Under China's Medical Device Classification Catalogue, all cardiovascular implantable and interventional devices — without exception — are classified as Class III medical devices, the highest risk tier. This classification reflects the devices' direct contact with the cardiovascular system, their extended or permanent implantation in the body, and the severity of potential adverse events.
The Class III designation has direct consequences for the registration pathway:
- Registration authority: National NMPA (not provincial bureaus)
- Technical review conducted by: Centre for Medical Device Evaluation (CMDE)
- Clinical evidence: comprehensive clinical data required (clinical trial or equivalence-based evaluation)
- Manufacturing inspection: mandatory on-site inspection of production facilities prior to approval
- Post-market surveillance: annual periodic safety reports, active adverse event monitoring
3. The Registration Process: From Application to Approval
What Registration Means
Medical device registration is the process by which a manufacturer submits an application to NMPA, which then evaluates safety, efficacy, and quality controllability — and decides whether to grant market approval. NMPA's technical review — conducted by CMDE — focuses on whether the evidence presented supports a conclusion that the device's benefits outweigh its risks for the intended patient population and use conditions.
The standard of proof is not certainty — it is a systematic, evidence-based assessment that the device can achieve its intended purpose in a clinically meaningful way, with risks that are acceptable given the available alternatives.
Registration Dossier Structure
A complete Class III cardiovascular device registration dossier typically includes:
| Module | Key Contents |
|---|---|
| Product Overview | Intended use, device description, technical principles, classification justification |
| Basic Principles Checklist (EP清单) | Systematic mapping of device characteristics to safety and performance requirements; evidence for each applicable requirement |
| Research and Testing Data | Performance testing, biocompatibility evaluation, sterilisation validation, shelf-life/stability data, electrical safety (if applicable) |
| Manufacturing Information | Materials, production process, quality control, GMP compliance evidence |
| Clinical Evaluation | Clinical trial data or equivalence-based clinical evaluation report; for devices on the clinical trial approval list, a separate clinical trial approval is required before the trial can begin |
| Product Technical Requirements | Detailed performance specifications and test methods, compliant with applicable national and industry standards |
| Instructions for Use / Labelling | Chinese-language IFU; contraindications, warnings, and precautions clearly stated |
On-Site Technical Review (现场审评)
For Class III cardiovascular devices, CMDE reviewers may conduct an on-site inspection of the manufacturer's facilities as part of the review process. The purpose is to verify the consistency between submitted dossier information and actual manufacturing practice. Review focus areas include:
- Design and development records (aligned with EP checklist claims)
- Raw material controls and traceability
- Production process management and process validation records
- In-process and finished product testing
On-site review is an opportunity — not merely a compliance hurdle. Companies that maintain rigorous documentation and can demonstrate live consistency between their paper submissions and their actual manufacturing practice move through this stage quickly.
4. Domestic Innovation: The Competitive Landscape Is Shifting
The near-parity between domestic and imported cardiovascular implant registrations is not a coincidence — it reflects a sustained, deliberate investment in domestic cardiovascular device development over the past decade.
Several factors have accelerated this shift:
- 14th Five-Year Plan priority designation: heart valve systems, ventricular assist devices, endovascular stent-grafts, neural stimulators, and joint replacements are all explicitly named as priority development targets
- Volume-based procurement (集采) pressure: centralised procurement has significantly compressed margins on coronary stents and other commoditised cardiovascular devices, driving both domestic companies and foreign manufacturers to move up the value chain toward more complex products
- Clinical infrastructure development: China now has over 1,000 centres capable of conducting TAVR procedures — a clinical network that supports both domestic innovation and foreign registration pathways requiring China-based trials or registry data
For foreign manufacturers, the competitive implication is clear: the window for premium-priced imported device dominance in standard cardiovascular categories is closing. The strategic premium now lies in high-complexity innovations where domestic competitors are still 3–5 years behind: next-generation transcatheter valves, bioresorbable scaffolds, haemodynamic monitoring implants, and combination device-drug products.
Cardiovascular implant registration in China is one of the most technically demanding and commercially consequential regulatory processes in the global device industry. The evidentiary standards are rigorous, the review is thorough, and the process rewards companies that have invested in high-quality preclinical and clinical data. NMPA's acceptance of overseas clinical data — when properly structured — is a genuine opportunity for foreign manufacturers to leverage global clinical programmes. The key is knowing what NMPA will and will not accept before you design your clinical strategy.